Rekah Pharmaceutical Industry Full Year 2024 Earnings: EPS: ₪0.54 (vs ₪0.60 loss in FY 2023)

Rekah Pharmaceutical Industry (TLV:REKA) Full Year 2024 Results

Key Financial Results

• Revenue: ₪321.7m (flat on FY 2023).
• Net income: ₪6.21m (up from ₪6.91m loss in FY 2023).
• Profit margin: 1.9% (up from net loss in FY 2023).
• EPS: ₪0.54 (up from ₪0.60 loss in FY 2023).

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Rekah Pharmaceutical Industry shares are down 7.3% from a week ago.

Risk Analysis

Before you take the next step you should know about the 2 warning signs for Rekah Pharmaceutical Industry (1 is a bit concerning!) that we have uncovered.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.